Please login to the form below

Not currently logged in
Email:
Password:

Onconova appoints Ajay Bansal as chief financial officer

He joins from Complete Genomics

Ajay Bansal Onconova TherapeuticsAjay Bansal has left Complete Genomics to join cancer specialists Onconova Therapeutics as chief financial officer and president

Bansal (pictured) served as chief financial officer at Complete Genomics since May 2010, having previously held the role of chief financial officer and executive VP of business development at Lexicon Therapeutics.

He joins US-based Onconova as the company prepares to complete enrolment for a phase III study to investigate lead drug candidate rigosertib in patients with myelodysplastic syndromes.

“The potential benefit of rigosertib for the treatment of patients with both solid and haematological malignancies presents a significant opportunity, and I look forward to helping the company meet its objectives for this compound and the rest of the pipeline,” said Bansal.

In addition to his prior roles at Complete Genomics and Lexicon, Bansal has also served as chief financial officer at Nektar Therapuetics and Tercica, later acquired by Ipsen.

8th April 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics